A vaccine for hypertension based on peptide AngI-R: A pilot study

International Journal of Cardiology

Volumn 148, Issue 1, 2011, Pages 76-84

  Hong, Fang ^a   Quan, Wu Yong ^b   Pandey, Rabindra ^a   Yi, Shen ^a   Chi, Liu ^a   Xia, Li Zhan ^a   Yuan, Ma ^a   Ming, Lou ^a  

^a TONGJI UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin converting enzyme inhibitory; Anti hypertensive; Immunization; Peptide

Indexed keywords

ANGIOTENSIN 1 RECEPTOR PEPTIDE; ANGIOTENSIN ANTIBODY; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II ANTIBODY; CAPTOPRIL; HORMONE ANTIBODY; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANGIOTENSIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; HEART MUSCLE CELL; HEART WEIGHT; HYPERTENSION; IMMUNE RESPONSE; MALE; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; HYPERTENSION; ISOANTIBODIES; MALE; PILOT PROJECTS; RABBITS; RANDOM ALLOCATION; RATS; RATS, INBRED SHR; VACCINES, SUBUNIT;

EID: 79952818659     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2009.10.027     Document Type: Article

References (25)

1. Bahraoui EM, Granier C, Rietschoten JV, Rochat H, Ayeb ME. Specificity and neutralizing capacity of antibodies elicited by a synthetic peptide of scorpion toxin. J Immunol May 1 1986;136(9):3371-7. (Pubitemid 16113927)
2. Beale J. Synthetic peptides as the basis for future vaccines. Nature Jul 1 1982;298(5869):14-5.
3. Brown MJ, Coltart J, Gunewardena K, Ritter JM, Auton TR, Glover JF. Randomized double-blind placebo-controlled study of anangiotensinimmunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) Aug 2004;107(2):167-73. (Pubitemid 39070933)
4. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation Apr 14 1998;97(14):1411-20. (Pubitemid 28182680)
5. Butler VP, Beiser SM. Antibodies to small molecules: biological and clinical applications. Adv Immunol 1973;17:255-311.
6. Christlieb AR, Biber TU, Hickler RB. Studies on the role of angiotensin in experimental renovascular hypertension: an immunologic approach. J Clin Invest Aug 1969;48(8): 1506-18.
7. Ellis R. Product development plan for new vaccine technologies. Vaccine Feb 8 2001;19 (13-14): 1559-66. (Pubitemid 32175712)
8. Gavras I, Gavras H. The renin-angiotensin systemin hypertensive cardiac disease. In: Ulfendahl HR, Aurell M, editors. Renin-angiotensin, a centenary symposium of the discovery of the renin-angiotensin system. London: Portland Press; 1997. p. 265-72.
9. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension Feb 1999;33(2):613-21. (Pubitemid 29091636)
10. Jackson DC, Fitzmaurice CJ, Brown LE, Zeng W. Preparation and properties of totally synthetic immunogens. Vaccine Sep 1999;18(3-4):355-61. (Pubitemid 29444011)
11. Johnston CI, Hutchinson JS, Mendelsohn FA. Biological significance of renin angiotensin immunization. Circ Res Oct 1970;27(Suppl 2):215t.
12. Lerner RA. Tapping the immunological repertoire to produce antibodies of predetermined specificity. Nature Oct 14 1982;299(5884):593-6.
13. Long L, Glover RT, Kaufman HL. The next generation of vaccines for the treatment of cancer. Curr Opin Mol Ther Feb 1999;1(1):57-63. (Pubitemid 29236620)
14. Messerli FH, Weber A, Brunner HR. Angiotensin II receptor inhibition. Arch Intern Med Sep 23 1996;156(17):1957-65.
15. Michel JB, Guettier C, Reade R, Sayah S, Corvol P,Menard J. Immunologic approaches to blockade of the renin-angiotensin system: a review. Am Heart J Mar 1989;117(3): 756-67.
16. Mitka Mike. Vaccine takes aim at hypertension. JAMA Dec 26 2007;298(24):2854-5.
17. Michel JB. Renin-angiotensin vaccine: old story, new project 'efficacy versus safety'. Clin Sci (Lond) Aug 2004;107(2):145-7.
18. Murray BA, FitzGerald RJ. Angiotensin converting enzyme inhibitory peptides derived from food proteins: biochemistry, bioactivity and production. Curr Pharm Des 2007;13(8):773-91. (Pubitemid 46591099)
19. Newman MJ, Powell MF. Immunological and formulation design considerations for subunit vaccines. In: Powell MF, Newman MJ, editors. Vaccine design: the subunit and adjuvant approach. New York: Plenum Press; 1995. p. 1-42.
20. Pandey R, Wu YQ, Fang Hong, Su LJ. Vaccine for hypertension: modulating the renin-angiotensin system. Int J Cardiol May 15 2009;134(2):160-8.
21. Patrice M, Alain C, Alma F, Patrik M, Juerg N, Robert S, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. Bachmann Journal of Hypertension Jan 2007;25(1):63-72.
22. Sunman W, Sever PS. Non-angiotensin effects of angiotensin-converting enzyme inhibitors. Clin Sci Dec 1993;85(6):661-70. (Pubitemid 23362926)
23. Sutcliffe JG, Shinnick TM, Green N, Lerner RA. Antibodies that react with predetermined sites on proteins. Science Feb 11 1983;219(4585):660-6. (Pubitemid 13185418)
24. Vanessa V, John VC, Willy V. Bioavailability of angiotensin I converting enzyme inhibitory peptides. Br J Nutr Sep 2004;92(3):357-66.
25. Coats AJ. Ethical authorship and publishing. Int J Cardiol 2009;131:149-50.